[1] 毛雨.糖尿病合并冠心病患者冠脉病变严重程度与肾功能的相关性研究[J].海南医学,2018,29(7):910-912. [2] 曹志伟. 参麦注射液对冠状动脉粥样硬化性心脏病患者血脂及心肌损伤因子的影响[J].中国药业,2016,25(11):40-42. [3] 徐向进, 潘长玉, 田慧, 等. WHO 及美国糖尿病学会糖尿病诊断标准在老年人群中应用的分析和评估 [J].中华内分泌代谢杂志, 2002, 18(5): 357-361. [4] Task Force Members, Montalescot G, Sechtem U,et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology[J].Eur Heart J,2013,34(38):2949-3003. [5] Zhang Z, Li X, La W,et al.Ginsenoside Re reduces insulin resistance through inhibition of c-Jun NH2-terminal kinase and nuclear factor-kappaB [J].Mol Endocrinol,2008, 22(1): 186-195. [6] Lee HM, Lee OH, Kim KJ,et al.Ginsenoside Rgl promotes glucose uptake through activated AMFK pathway in insulin-resistant muscle cells [J].Phytother Res,2012, 26(7): 1017-1022. [7] 毛玉山, 陈轶尘, 赵亚荣,等. 参麦注射液改善3T3-L1细胞的胰岛素抵抗[J].中国病理生理杂志,2015,31(12):2233-2238. [8] 杨尚敏. 参麦注射液辅助治疗稳定性心绞痛43例疗效观察 [J].山东医药, 2004, 44(35): 74. [9] 范丽勇,杨洁,吕树志. 参麦注射液对冠心病患者血管内皮功能及炎性反应的影响研究[J].实用心脑肺血管病杂志,2016,24(2):84-86. [10] 邓敏. 参麦注射液联合常规治疗用于冠心病的疗效观察[J].中国医院用药平均与分析,2018,18(2):177-178.
2019, Vol. 36 
